Top of page Skip navigation

    Thank you to everyone that joined us this year

Wednesday 24 May
15.00 onwards

Arrival and check-in

15.30 - 16.30

New for 2017...we invite delegates to join us at one of two pre-forum sessions 

Innovation, diversity and talent in Life Science

This pre-session roundtable will focus on a number of key issues currently facing innovative life science companies in the UK with regards to their people and talent strategies.  With so many life science companies, large and small, concerned about the implications of Brexit and a potentially restrictive immigration mindset on their organisations and on the science base that feeds our ecosystem – we explore the essential role that diversity in all its iterations plays both in terms of innovation culture, company performance, and in attracting and retaining the very best talent.

Facilitated by

Nick Stephens
Executive Chairman, The RSA Group

Thomas Schleimer
Partner, The RSA Group

16.00 - 17.00

Getting your story across - how to present to investors

In this session we'll hear from the experts on how to get your business ready for those all-important investment meetings. Aimed at private companies looking at VC rounds or preparing for the public markets and those younger public companies.

Dr Chris Gardner
Partner, Consilium Strategic Communications

Kate Bingham
Managing Partner, SV Health Investors

Dr Stefan Hamill
Director, Healthcare and Life Sciences Equity Research, Numis Securities

David Hipkiss
BIA Board

17.00 - 18.15

Leisure time

18.15 - 19.15

Networking drinks reception

19.15 - 20.00


Steve Bates OBE
Chief Executive Officer, BIA

followed by a fireside chat with

Kate Bingham
Partner, SV Health Investors

20.00 onwards

Evening Dinner followed by drinks in the bar

Thursday 25 May
07.45 - 08.45

Networking Breakfast

08.45 - 08.55


Dr Jane Osbourn
Vice President Research and Development, MedImmune and Chair, BIA

08.55 - 09.10

Influencing and shaping the sector 

Laura Collister
Interim Head of Communications and Public Affairs, BIA

Dr Martin Turner
Policy and Projects Manager, BIA

09.10 - 10.00

Disruption, innovation and societal change

What does the future hold for Biotechnology companies?  In this session, we look at the potential disruptive technologies, innovations and societal imperatives that will change our industry

Jo Pisani
Partner, Strategy&, PwC

Gerard Brophy
Chief Technology Officer, GE Healthcare 

Rt Hon the Lord Drayson of Kensington 

Chairman and Chief Executive Officer, Drayson Technologies

Dr Jackie Hunter
Chief Executive Officer, Benevolent 

Sumit Jamuar
Chairman and Chief Executive Officer, Global Gene Corps 

Dmitry Kaminskiy
Founder and Senior Partner, Deep Knowledge Ventures 


10.00 - 10.45

Investment from the East – what are the real opportunities for Biotech?

At current growth rates, China is forecast to overtake the US to become the world's largest funder of R&D in 2022.  We look at current and future opportunities and complexities for UK biotechnology companies, and listen to the experiences of seasoned investors.

John Hodgson
Executive Editor, Informa

Dr David Chiswell OBE
Chief Executive Officer, Kymab

Peter Crane
Founder and Chief Executive Officer EO, Rare Pharma and Chief Global Business Development Officer, Innovation Forum 

Simon Haworth
Founder at Dynasty Bio, BSG Team Ventures and Team Kapital Dynasty Biotechnology and the Sino-UK Fund

Dr Andy Richards CBE
Biotech Entrepreneur 

Rob Scott
Director, China Bluesky Partners 

10.45 - 11.15

Refreshments and networking

11.15 - 12.00

Trump's America and the impact on Life Sciences

Our experts look at what is happening in the sector’s largest market and indications so far as to what Trump’s administration and approaches will mean for the Industry

Kevin Pojasek
Vice President, Director of Corporate Strategy , Immunocore

David Crow
Senior US Business Correspondent, FT 

Jeanne Haggerty
Senior Vice President, Federal Government Relations, BIO 

Louise Leong
Director Science Relations, AstraZeneca

12.00 - 12.45

Future of funding for UK biotech
Combining discussions from the day we bring together key experts for a final view on the future of funding for UK biotech companies. We’ll explore additional innovative forms of funding to present a picture of the options available, discuss the funding gaps that persist and new funding models and sources.

David Mardle
Partner, Taylor Wessing

Richard Jones
Chief Financial Officer, Mereo Biopharma

Jeremy Landau
Corporate Finance Partner, Taylor Wessing 

David Pinniger
Fund Manager, Polar Capital 

Phil Walker
Head of Healthcare, Corporate Finance, Zeus Capital 


12.45 - 13.00

Funding for innovation and the British Business Bank

Alice Hu-Wagner
Managing Director, Strategy Economics and Business Development, British Business Bank

13.00 - 14.00

Lunch and networking

14.00 - 14.45

Innovation showcase

Our popular showcase session will see  BIA  member companies present their new innovations and or technologies.

Dr David Horna
Founder and Director, Aglaris 

Dr Rick Livesey
Chief Executive Officer, Gen2 Neuroscience

James McIlroy
Chief Executive Officer, EnteroBiotix

Angela Silmon
Chief Executive, NewGene

Sumi Biswas
Chief Executive Officer and  Co-Founder, SpyBiotech

14.45 - 15.30

The biotech pipeline.. pushing the innovation agenda forward

In this session our panel of pharma and biotech collaborators discuss how they are developing their strategies for the future to promote the biotechnology ecosystem 

Mark Thompson
Partner, Sidley

James Critchley
Vice President, PJT Partners

Dr Jane Osbourn
Vice President Research and Development, MedImmune and Chair, BIA

Dr Nerida Scott
Vice President Transactions, J&J Innovation

15.30 - 16.20

What does the general election mean for life sciences

More details to follow

16.20 - 16.30

Summary and close